BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 12748124)

  • 21. DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells.
    Murphy SP; Holtz R; Lewandowski N; Tomasi TB; Fuji H
    J Immunol; 2002 Sep; 169(6):3085-93. PubMed ID: 12218125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.
    Steimle V; Siegrist CA; Mottet A; Lisowska-Grospierre B; Mach B
    Science; 1994 Jul; 265(5168):106-9. PubMed ID: 8016643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation.
    Morris AC; Beresford GW; Mooney MR; Boss JM
    Mol Cell Biol; 2002 Jul; 22(13):4781-91. PubMed ID: 12052885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells.
    Chou SD; Khan AN; Magner WJ; Tomasi TB
    Int Immunol; 2005 Nov; 17(11):1483-94. PubMed ID: 16210330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
    Radosevich M; Jager M; Ono SJ
    Exp Mol Pathol; 2007 Feb; 82(1):68-76. PubMed ID: 16650406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
    Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
    Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.
    Naves R; Lennon AM; Barbieri G; Reyes L; Puga G; Salas L; Deffrennes V; Rosemblatt M; Fellous M; Charron D; Alcaïde-Loridan C; Bono MR
    Int Immunol; 2002 May; 14(5):481-91. PubMed ID: 11978778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha.
    Nikcevich KM; Piskurich JF; Hellendall RP; Wang Y; Ting JP
    J Neuroimmunol; 1999 Oct; 99(2):195-204. PubMed ID: 10505975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression.
    Zika E; Fauquier L; Vandel L; Ting JP
    Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16321-6. PubMed ID: 16254053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The arginine methyltransferase PRMT5 regulates CIITA-dependent MHC II transcription.
    Fan Z; Kong X; Xia J; Wu X; Li H; Xu H; Fang M; Xu Y
    Biochim Biophys Acta; 2016 May; 1859(5):687-96. PubMed ID: 26972221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells.
    Kong X; Fang M; Li P; Fang F; Xu Y
    J Mol Cell Cardiol; 2009 Mar; 46(3):292-9. PubMed ID: 19041327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells.
    Butticè G; Miller J; Wang L; Smith BD
    Circ Res; 2006 Mar; 98(4):472-9. PubMed ID: 16439692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
    Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
    Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of distinct regions of 5' flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene.
    Piskurich JF; Wang Y; Linhoff MW; White LC; Ting JP
    J Immunol; 1998 Jan; 160(1):233-40. PubMed ID: 9551976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional control of MHC genes in fetal trophoblast cells.
    van den Elsen PJ; Gobin SJ; van der Stoep N; Datema G; Viëtor HE
    J Reprod Immunol; 2001; 52(1-2):129-45. PubMed ID: 11600183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TNF-alpha suppresses IFN-gamma-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNA.
    Han Y; Zhou ZH; Ransohoff RM
    J Immunol; 1999 Aug; 163(3):1435-40. PubMed ID: 10415044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA).
    Takamura Y; Ikeda H; Kanaseki T; Toyota M; Tokino T; Imai K; Houkin K; Sato N
    Glia; 2004 Mar; 45(4):392-405. PubMed ID: 14966870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.
    Kanaseki T; Ikeda H; Takamura Y; Toyota M; Hirohashi Y; Tokino T; Himi T; Sato N
    J Immunol; 2003 May; 170(10):4980-5. PubMed ID: 12734341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression.
    Dong Y; Tang L; Letterio JJ; Benveniste EN
    J Immunol; 2001 Jul; 167(1):311-9. PubMed ID: 11418665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.
    Deffrennes V; Vedrenne J; Stolzenberg MC; Piskurich J; Barbieri G; Ting JP; Charron D; Alcaïde-Loridan C
    J Immunol; 2001 Jul; 167(1):98-106. PubMed ID: 11418637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.